Voyager Therapeutics (NASDAQ:VYGR) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Thursday,Benzinga reports. The firm currently has a $14.00 price target on the stock.

A number of other analysts also recently commented on VYGR. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Wedbush reduced their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Voyager Therapeutics Trading Down 9.3 %

VYGR stock opened at $5.64 on Thursday. The company has a market cap of $308.11 million, a price-to-earnings ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a 12 month low of $5.59 and a 12 month high of $11.72. The firm has a 50-day moving average of $6.62 and a two-hundred day moving average of $7.50.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the firm earned ($0.59) EPS. As a group, equities analysts forecast that Voyager Therapeutics will post -1.2 earnings per share for the current year.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.53% of the stock is owned by insiders.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of Voyager Therapeutics by 198.6% in the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after acquiring an additional 32,437 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Voyager Therapeutics by 8.2% in the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock worth $367,000 after acquiring an additional 2,975 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics in the first quarter worth $101,000. Vanguard Group Inc. grew its stake in shares of Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Voyager Therapeutics by 10.1% in the first quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock worth $4,280,000 after acquiring an additional 42,029 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.